John M Lambert

Summary

Affiliation: ImmunoGen Inc
Country: USA

Publications

  1. ncbi Drug-conjugated monoclonal antibodies for the treatment of cancer
    John M Lambert
    ImmunoGen Inc, Cambridge, MA 02139, USA
    Curr Opin Pharmacol 5:543-9. 2005
  2. pmc Drug-conjugated antibodies for the treatment of cancer
    John M Lambert
    ImmunoGen, Inc, 830 Winter Street, Waltham, MA 02451, USA
    Br J Clin Pharmacol 76:248-62. 2013
  3. pmc Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
    Lintao Wang
    ImmunoGen, Inc, 128 Sidney Street, Cambridge, MA 02139, USA
    Protein Sci 14:2436-46. 2005
  4. ncbi Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry
    Lintao Wang
    ImmunoGen, Inc, Cambridge, Maryland 02139, USA
    Pharm Res 22:1338-49. 2005
  5. doi Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates
    Robert Y Zhao
    ImmunoGen, Inc, 830 Winter Street, Waltham, Massachusetts 02451, United States
    J Med Chem 54:3606-23. 2011
  6. ncbi Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
    Alexandru C Lazar
    ImmunoGen, Inc, 128 Sidney Street, Cambridge, MA 02139, USA
    Rapid Commun Mass Spectrom 19:1806-14. 2005
  7. pmc ADME of antibody-maytansinoid conjugates
    Hans K Erickson
    ImmunoGen, Inc, 830 Winter Street, Waltham, Massachusetts 02451, USA
    AAPS J 14:799-805. 2012
  8. doi Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
    Gail D Lewis Phillips
    Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 68:9280-90. 2008
  9. doi Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer
    Robert Yongxin Zhao
    ImmunoGen, Inc, 830 Winter Street, Waltham, Massachusetts 02451, United States
    J Med Chem 55:766-82. 2012
  10. doi Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage
    Brenda A Kellogg
    ImmunoGen, Inc, 830 Winter Street, Waltham, Massachusetts 02451, United States
    Bioconjug Chem 22:717-27. 2011

Collaborators

Detail Information

Publications16

  1. ncbi Drug-conjugated monoclonal antibodies for the treatment of cancer
    John M Lambert
    ImmunoGen Inc, Cambridge, MA 02139, USA
    Curr Opin Pharmacol 5:543-9. 2005
    ..Thirty years after the discovery of monoclonal antibodies, this new generation of highly potent compounds could yield targeted cytotoxic agents that are effective treatments for many cancers...
  2. pmc Drug-conjugated antibodies for the treatment of cancer
    John M Lambert
    ImmunoGen, Inc, 830 Winter Street, Waltham, MA 02451, USA
    Br J Clin Pharmacol 76:248-62. 2013
    ..Thus these, and other ADCs in development, promise to achieve the long sought goal of ADC technology, that is, of having compounds with high anti-tumour activity at doses where adverse effects are generally mild. ..
  3. pmc Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
    Lintao Wang
    ImmunoGen, Inc, 128 Sidney Street, Cambridge, MA 02139, USA
    Protein Sci 14:2436-46. 2005
    ..Using structural models of human IgG1, it was found that modified lysine residues were on the surface in areas of structural flexibility and had large solvent accessibility...
  4. ncbi Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry
    Lintao Wang
    ImmunoGen, Inc, Cambridge, Maryland 02139, USA
    Pharm Res 22:1338-49. 2005
    ....
  5. doi Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates
    Robert Y Zhao
    ImmunoGen, Inc, 830 Winter Street, Waltham, Massachusetts 02451, United States
    J Med Chem 54:3606-23. 2011
    ....
  6. ncbi Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
    Alexandru C Lazar
    ImmunoGen, Inc, 128 Sidney Street, Cambridge, MA 02139, USA
    Rapid Commun Mass Spectrom 19:1806-14. 2005
    ..6 drug molecules per antibody molecule, the experimental conditions needed to be carefully selected to allow acquisition of the whole spectrum containing the charge envelopes of all species...
  7. pmc ADME of antibody-maytansinoid conjugates
    Hans K Erickson
    ImmunoGen, Inc, 830 Winter Street, Waltham, Massachusetts 02451, USA
    AAPS J 14:799-805. 2012
    ..In addition, all three ADCs were effectively detoxified during hepatobiliary elimination in rodents...
  8. doi Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
    Gail D Lewis Phillips
    Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 68:9280-90. 2008
    ..Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clinical development...
  9. doi Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer
    Robert Yongxin Zhao
    ImmunoGen, Inc, 830 Winter Street, Waltham, Massachusetts 02451, United States
    J Med Chem 55:766-82. 2012
    ..The prodrugs can be converted to the active cytotoxic compounds through the action of endogenous phosphatases. Antibody-prodrug conjugates displayed potent antigen-selective cytotoxic activity in vitro and antitumor activity in vivo...
  10. doi Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage
    Brenda A Kellogg
    ImmunoGen, Inc, 830 Winter Street, Waltham, Massachusetts 02451, United States
    Bioconjug Chem 22:717-27. 2011
    ....
  11. ncbi A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates
    Michael S Fleming
    ImmunoGen Inc, 128 Sidney Street, Cambridge, MA 02139, USA
    Anal Biochem 340:272-8. 2005
    ..The method was also used to estimate drug per MAb ratios, which were consistent with those determined by UV spectroscopy...
  12. ncbi Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice
    Hongsheng Xie
    ImmunoGen, Inc, Cambridge, MA 02139, USA
    J Pharmacol Exp Ther 308:1073-82. 2004
    ..Tissue distribution studies with (125)I-labeled conjugate and antibody showed antibody-like behavior for the conjugate; the antibody of the conjugate did not distribute or bind significantly to any solid tissue...
  13. ncbi A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors
    Paul R Helft
    University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 10:4363-8. 2004
    ..v. infusion without interruption...
  14. ncbi Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 21:211-22. 2003
    ..v.) once every 3 weeks and to seek evidence of antitumor activity...
  15. ncbi Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth
    Antonio T Baines
    Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Methods Enzymol 407:556-74. 2006
    ..Finally, we also compare the use of constitutive and inducible shRNA expression vectors for analyses of mutant Ras function...
  16. ncbi Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism
    John M Lambert
    Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Nat Cell Biol 4:621-5. 2002
    ..Furthermore, activated Ras and Tiam1 cooperate to cause synergistic formation of Rac-GTP in a PI(3)K-independent manner. Thus, Tiam1 can function as an effector that directly mediates Ras activation of Rac...